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between a variant of the Peroxisome Proliferator-
Activated Receptor Gamma (PPAR-γ) gene and
systemic sclerosis
Roberta Goncalves Marangoni1*†, Benjamin D Korman1†, Yannick Allanore2,3, Philippe Dieude4, Loren L Armstrong5,
Margarita Rzhetskaya5, Monique Hinchcliff1, Mary Carns1, Sofia Podlusky1, Sanjiv J Shah6, Barbara Ruiz2,
Eric Hachulla7, Kiet Tiev8, Jean-Luc Cracowski9, John Varga1,10 and M Geoffrey Hayes5,11,12*Abstract
Introduction: The multifunctional nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) has
potent anti-fibrotic effects, and its expression and activity are impaired in patients with systemic sclerosis (SSc). We
investigated PPAR-γ gene (PPARG) single nucleotide polymorphisms (SNPs) associated with SSc.
Methods: Tag SNPs spanning PPARG were genotyped in a European ancestry US discovery cohort comprising 152
SSc patients and 450 controls, with replication of our top signal in a European cohort (1031 SSc patients and 1014
controls from France). Clinical parameters and disease severity were analyzed to evaluate clinical associations with
PPARG variants.
Results: In the discovery cohort, a single PPARG intronic SNP (rs10865710) was associated with SSc (p = 0.010; odds
ratio = 1.52 per C allele, 95% confidence interval 1.10-2.08). This association was replicated in the French validation
cohort (p = 0.052; odds ratio = 1.16 per C allele, 95% confidence interval 1.00-1.35). Meta-analysis of both cohorts
indicated stronger evidence for association (p = 0.002; odds ratio = 1.22 per C allele, 95% confidence interval
1.07-1.40). The rs10865710 C allele was also associated with pulmonary arterial hypertension in the French SSc
cohort (p = 0.002; odds ratio = 2.33 per C allele, 95% confidence interval 1.34-4.03).
Conclusions: A PPARG variant is associated with susceptibility to SSc, consistent with a role of PPAR-γ in the
pathogenesis of SSc.Introduction
Systemic sclerosis (SSc) is a chronic multisystem disease of
unknown etiology. The hallmarks of SSc are microvascular
dysfunction, autoimmune reactivity and organ fibrosis
[1,2]. Systemic sclerosis shows substantial heterogeneity in
its clinical manifestations, patterns of organ involvement
and natural history [3]. Interstitial lung disease (ILD) and* Correspondence: roberta.marangoni@northwestern.edu; ghayes@northwestern.edu
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stated.pulmonary arterial hypertension (PAH) are major com-
plications that portend a poor prognosis [2,4,5]. The eti-
ology and pathogenesis of SSc remain poorly understood.
Mounting evidence supports the role of genetic factors [6].
Recent studies have established genome-wide signifi-
cant associations of SSc with the major histocompatibil-
ity complex (MHC) region as well as CD247, IRF5, IRF8,
STAT4, and nominal significance at GRB10, JAZF1,
KIAA0319L, PXK, RHOB1, RPL41 and SOX5 [7-10].
Genome-wide association follow-up studies have re-
vealed significant additional association at ATG5, DNA-
SE1L3, CSK, SCHIP1-IL12A, IL12RB1, IL12RB2, NFKB1,
PPARG, PSD3 and TNIP1 [11-16]. In addition, signifi-
cant SSc associations have been derived from candidatetral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Clinical characteristics of SSc patients included in
the discovery and replication sets
US
cohort
French
cohort
P-value
Patients genotyped, n* 152 1031
Female 78 86 0.012
Diffuse cutaneous systemic sclerosis 35 31 0.578
Limited cutaneous systemic sclerosis 63 63 0.578
Anticentromere antibody-positive 22 41 <0.001
Anti-topoisomerase I antibody-positive 23 28 0.860
Interstitial lung disease 57 38 <0.001
Pulmonary hypertension 7 7 0.976
*Unless otherwise indicated, values indicate percentages. Bold P-values are
those that are statistically significant at P <0.05 (Student’s t-test).
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BLK, CD226, IL2RA, KCNA5 and TLR2 [3,11]. Interest-
ingly, nearly all of these genetic studies implicate genes
involved in adaptive or innate immunity that have been
also associated with other autoimmune diseases includ-
ing rheumatoid arthritis, systemic lupus erythematosus,
psoriasis, and inflammatory bowel disease [17]. Notwith-
standing the prominent fibrotic and vasculopathic fea-
tures of SSc, genetic studies to date have failed to
identify major risk factors related to genes involved in
the processes of fibrosis or vascular homeostasis [18].
Progressive fibrosis in the skin and multiple organs con-
tributes to organ failure in SSc, and is ascribed to dere-
gulated fibroblast activation [1]. We have focused our
research on the multifunctional nuclear receptor peroxi-
some proliferator activated receptor-gamma (PPAR-γ).
Our findings, subsequently confirmed by others, have de-
lineated unexpected potent anti-fibrotic effects of PPAR-γ
in vitro and in vivo [19-24]. Moreover, we and others have
shown that the expression and activity of PPAR-γ are im-
paired in fibroblasts, lesional skin, and lung tissue from
patients with SSc, implicating PPAR-γ as a potentially
important factor in pathogenesis [22,25]. Mice deficient
in PPAR-γ show increased susceptibility to bleomycin-
induced fibrosis [26]. Additionally, serum levels of adipo-
nectin, a direct PPARG transcriptional target, are reduced
in patients with SSc [27].
In multiple cell types, PPAR-γ is a direct target, and is
responsible for the anti-diabetic effects of the glitazone
class of drugs [28]. At the cellular level, PPAR-γ regulates
adipocyte differentiation, insulin sensitivity, and fat metab-
olism, and has also been implicated in modulating im-
munity and inflammation [29,30]. Dysfunction of PPAR-γ
is implicated in diverse pathologies including diabetes, glo-
merulosclerosis, atherosclerosis and pulmonary artery
hypertension (PAH) [31].
In light of the potential role of PPAR-γ in pathogenesis
of SSc, we hypothesized that genetic variants in the PPARG
may influence disease susceptibility. Two coding, non-
synonymous PPARG polymorphisms (rs1801282 (P12A)
and rs3856806 (C141T)) have been extensively studied in
diabetes, coronary artery disease, the metabolic syndrome,
and non-alcoholic fatty liver disease [32-35]. The P12A
variant has been associated with increased insulin sensitiv-
ity, lower body mass and protection from type 2 diabetes
[35], while the C161T variant has been associated with in-
creased body weight [34]. In the present studies we sought
to conduct a candidate gene association approach to inves-
tigate common variants in the PPARG gene with SSc.
Methods
Study populations
Patients with SSc were evaluated at the Northwestern
Scleroderma Program between 2005 and 2009. Patientsand controls were enroled in NUgene, a Northwestern
University biobank in which participants gave qualified in-
vestigators de-identified access to their retrospective and
longitudinal electronic medical record (EMR) information,
as well as a blood draw for DNA extraction coded to match
their EMR information to conduct genetic studies [36].
These patients self-reported as having European ancestry.
The cohort consisted of 152 SSc patients (53 with diffuse
cutaneous SSc (dcSSc), 96 with limited cutaneous SSc
(lcSSc), and 2 patients who were unclassified). All patients
fulfilled American College of Rheumatology (ACR) criteria
for SSc and cutaneous subsets were defined according to
the criteria of LeRoy et al. [37,38]. Each SSc patient was
matched by age, gender, and ancestry to three NUgene bio-
bank controls without evidence of SSc or other clinical
autoimmune diseases according to self-report or by ICD-9
codes generated in the course of their clinical care at
Northwestern. This study was approved by the institutional
review board of Northwestern University, written informed
consent was acquired and blood was obtained. The demo-
graphic and clinical characteristics of patients with SSc in
the discovery and replication sets are presented in Table 1.
A replication study was performed using a French cohort
consisting of 1,031 SSc patients and 1,014 matched controls
[39,40]. Both the US discovery and French replication stud-
ies included only individuals of European ancestry, defined
as having four grandparents of European ancestry.
Assessment of clinical and laboratory parameters
Clinical and laboratory information obtained at the time of
blood sampling included age, gender, race/ethnicity, disease
duration (defined as the interval from first SSc-related non-
Raynaud event), forced vital capacity (FVC) and carbon
monoxide diffusion capacity (DLCO), both expressed as
percent of predicted, and high-resolution computerized
tomography (HRCT) of the chest. Interstitial lung disease
was defined as the presence of pulmonary reticular infil-
trates and/or honeycomb cysts on HRCTand/or FVC ≤70%
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was performed by echo/Doppler and PH was provisionally
defined as estimated pulmonary artery systolic pressure
≥40 mmHg; thereafter, the diagnosis was confirmed by
right heart catheterization using mean pulmonary artery
pressure ≥25 mmHg and capillary pressure <15 mmHg as
cut-off values. Anticentromere antibodies (ACA) were
detected by indirect immunofluorescence and anti-
topoisomerase I antibodies (ATA) were detected by pas-
sive immunodiffusion against calf thymus extract (Inova
Diagnostics) or by counterimmunoelectrophoresis.
Selection of single nucleotide polymorphisms (SNPs)
genotyped in each cohort
In the US cohort, the tag SNP Picker utility in HapMap
[53] was used to select SNPs spanning the 37.5 kb
PPARG gene and 5 kb up- and downstream to tag com-
mon variants in the region [41]. The nine tag SNPs were
selected to capture HapMap variants with ≥20% minor
allele frequency (MAF) with pairwise r2 ≤ 0.8 in the
European ancestry population (CEU). There was no evi-
dence of long-range linkage disequilibrium (LD) with
other genes in the region based on CEU data (Additional
file 1). For replication we examined rs10865710 in the
French cohort.
Genotyping
DNA was extracted from blood samples from all
NUgene SSc cases and matched controls using the Gen-
tra Autopure LS at the Northwestern University Center
for Genetic Medicine Genomics Core Facility. Genotyp-
ing was conducted using competitive allele-specific PCR
assays (KASP) at KBioscience (Hoddesdon, UK). Cases
and controls were randomly distributed across the geno-
typing plates, and there were no significant plate or
batch effects. We removed 19 samples that had four or
more (≥25%) SNP assays fail, after which the mean per
SNP call rate was 99.3%. Blind duplicates revealed a
99.6% genotyping concordance rate.
In the French cohort, genotyping was performed also
using KASP assays at KBioscience. The average genotype
completeness was 99% for both the SSc and the control
samples. Accuracy was >99%, according to duplicate
genotyping of 10% of all samples using the Taqman SNP
genotyping assay-allelic discrimination method (Applied
Biosystems).
Statistical analysis
All SNPs were tested for departures from Hardy-
Weinberg equilibrium by the chi squared goodness-of-fit
test. To test each SNP for association with SSc and
subgroups, we computed the overall allelic test of asso-
ciation using the chi squared statistic calculated from
two-by-two tables; association statistics and LD patternswere analyzed using Haploview version 4.2 [42]. Meta-
analysis of the combined US and French cohorts was
performed using the Cochran-Mantel-Haenszel statis-
tical test, and heterogeneity was assessed by calculating
I2 as described by Higgins et al. [43]. We had 80% power
to detect associations of odds ratios (ORs) ≥1.3 for SNPs
with a risk allele frequency of 20 to 80% in the US co-
hort at a discovery P-value of 0.006 (Bonferroni correc-
tion of P = 0.05/nine SNPs).
Results
Association tests of PPARG SNPs with SSc
No significant deviations from Hardy-Weinberg equilib-
rium (P <0.05) were observed for any of the nine SNPs
genotyped. In the US population, one SNP (rs10865710)
located on the first intron of PPARG (Table 2) achieved
uncorrected statistical significance (P = 0.010; OR = 1.52
(95% CI 1.10, 2.08) per C allele) and narrowly missed
our multiple-testing-corrected significance threshold of
P = 0.006 for association with SSc. To test the robustness
of this association, this SNP was then genotyped in the
French cohort and found to trend towards association
with SSc (P = 0.052, OR = 1.16 per C allele, 95% CI 1.00,
1.35). Meta-analysis of the results from the discovery and
replication cohorts was performed for SNP rs10865710 in
a total combined study population of 1,145 SSc patients
and 1,428 controls. The meta-analysis strengthened the
association between SSc and rs10865710 (P = 0.002, OR =
1.22 per C allele, 95% CI 1.07, 1.40) with no significant evi-
dence for heterogeneity between the two populations
(Table 3). We also conducted genotype based tests under
dominant and recessive models and found no statistically
significant evidence at a Bonferroni-corrected threshold
(P <0.006) that dominant or recessive models better fit
the data than under an additive allelic model.
Association with disease subtypes and clinical
characteristics
Significant associations of rs10865710 were observed
with both the lcSSc and dcSSc when each subtype was
compared to controls. In the US cohort, this SNP was
associated with lcSSc (P = 0.004, OR = 1.78 per C allele,
95% CI 1.19, 2.65), whereas in the French cohort this
SNP was associated with dcSSc (P = 0.002, OR = 1.43 per
C allele, 95% CI 1.14, 1.81) (Table 3; Additional file 2).
Meta-analyses of the US and French results revealed that
both lcSSc (P = 0.028, OR = 1.16 per C allele, 95% CI
1.00, 1.36) and dcSSc (P = 0.002, OR = 1.37 per C allele,
95% CI 1.11, 1.69) were associated with this SNP. Signi-
ficant heterogeneity between the two populations was
observed for lcSSc, and after adjusting for this the associ-
ation between rs10865710 was no longer significant
(Table 3). Testing for associations with SSc-specific auto-
antibodies and clinical manifestations (ILD, PH) within
Table 3 Meta-analysis of rs10865710 association with SSc subtypes in the US and French cohorts
Overall lcSSc dcSSc
Cases Controls Cases Controls Cases Controls
US Number 152 450 96 450 53 450
C, % 80.6 73.2 83.3 73.2 75.5 73.2
G, % 19.4 26.8 16.7 26.8 24.5 26.8
P-value 0.010 0.004 0.619
Odds ratio (95% CI) 1.52 (1.10, 2.08) 1.78 (1.19, 2.65) 1.12 (0.71, 1.78)
French Number 993 978 632 978 303 978
C, % 79.0 76.4 77.6 76.4 82.3 76.4
G, % 21.0 23.6 22.4 23.6 17.7 23.6
P-value 0.052 0.438 0.002
Odds ratio (95% CI) 1.16 (1.00, 1.35) 1.07 (0.90, 1.27) 1.43 (1.14, 1.81)
Meta-analysis Number 1145 1428 728 1428 356 1428
Fixed effects P-value 0.002 0.028 0.002
Odds ratio (95% CI) 1.22 (1.07, 1.40) 1.16 (1.00, 1.36) 1.37 (1.11, 1.69)
I2 33.6 41.5 0
P-value 0.134 0.024 0.376
Random-effects P-value 0.432
SSc = systemic sclerosis; lcSSc = limited cutaneous SSc; dcSSc = diffuse cutaneous SSc; OR = odds ratio; 95% CI = 95% confidence interval. ORs are in reference to
the risk allele. I2 = Higgins et al. test for heterogeneity. Bold indicates statistically significant P-values.
Table 2 Summary of association of nine PPARG SNPs genotyped in US and French case-control cohorts
US French Meta-analysis
SNP Location Risk/protective
alleles
Risk allele frequency P-value Odds ratio Odds ratio Odds ratio I2 (P-value)
(chr 3) Cases Controls (95% CI) P-value (95% CI) P-value (95% CI)
rs2972164 12309416 T/C 0.51 0.48 0.349 1.17
(0.90, 1.53)
rs7620165 12319441 G/A 0.36 0.35 0.679 1.06
(0.80, 1.39)
rs10865710 12328198 C/G 0.81 0.73 0.010 1.52 0.052 1.16 0.002 1.22 33.6
(1.10, 2.08) (1.00, 1.35) (1.07, 1.40) (0.134)
rs10510418 12363563 C/A 0.35 0.34 0.592 1.07
(0.82, 1.41)
rs4135247 12371588 G/A 0.45 0.39 0.092 1.25
(0.96, 1.63)
rs2959273 12417731 C/T 0.62 0.62 0.999 1.00
(0.76, 1.30)
rs1151999 12422153 C/A 0.52 0.49 0.353 1.13
(0.87, 1.46)
rs709151 12429999 G/A 0.66 0.64 0.539 1.09
(0.82, 1.43)
rs1175540 12440243 C/A 0.65 0.64 0.736 1.04
(0.79, 1.37)
SNP, single-nucleotide polymorphism; chr, chromosome; SSc, systemic sclerosis; I2, Higgins et al. test for heterogeneity. Bold indicates statistically significant P-values.
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with PH in the French cohort (P = 0.002, OR = 2.33 per C
allele, 95% CI 1.34, 4.03), and in the US-French meta-
analysis (P = 0.001, OR = 2.38 per C allele, 95% CI 1.40,
4.03) (Additional file 3).
Discussion
We report an association between SSc and genetic vari-
ation within the PPARG gene. This novel finding along
with a recent report of association of SSc with an SNP
70 kb upstream of the PPARG locus add to the mount-
ing evidence of the importance of PPAR-γ in SSc [13].
PPAR-γ is a multi-functional nuclear receptor impli-
cated in a diverse range of metabolic and degenerative
diseases, and increasingly in SSc and other fibrotic dis-
orders [26]. This case-control study provides evidence
supporting our hypothesis for an association between
common variants in the PPARG locus and SSc in European
ancestry populations. The PPARG rs10865710-C sus-
ceptibility allele was associated with SSc in the US co-
hort, trended towards association in the French cohort,
and was significantly associated in a combined sample
of 1,145 patients and 1,428 controls. The C allele was
associated with a 1.22-fold increase in the odds of sus-
ceptibility to SSc over the G allele in the combined
meta-analysis, and the population-specific ORs ranged
from 1.16 (French) to 1.52 (US).
The association signal observed between the rs10865710-
C and SSc is most likely not derived from the coding
variants rs1801282 (P12A) and rs3856806 (C161T)
previously associated with diabetes and coronary artery
disease [32,34,35] because they are not in strong LD
with rs10865710 (r2 = 0.31 and 0.14 for P12A and
C161T, respectively). Given the limited power of our
study we were not able to test for associations at these
or any other SNPs with MAF <20% as observed for
these two coding variants. There is also no evidence of
long-range LD between rs10865710 and other nearby
loci; LD between rs10865710 and all chromosome-3
SNPs with MAF ≥5% from HapMap phase-II CEU
samples showed no SNP >150 kb from rs10865710
with r2 ≥ 0.8. This demonstrates that the effect of the
associated SNP is unlikely to be modulating any gene
other than PPARG.
It is noteworthy that the rs10865710 PPARG associ-
ation with SSc has not been found in genome-wide asso-
ciation studies (GWAS0 [7-10]. This may be due to the
low effect size limiting the power to achieve genome-
wide significance. In fact, a recent GWAS follow-up
study found an association of rs310746, an intergenic
SNP 70 kb upstream of the PPARG locus, with SSc
nearly reaching genome-wide significance [13] and larger
meta-analyses will be required to elucidate this. This ef-
fect is likely to be independent of the associationbetween SSc and rs10865710 given the low LD between
these two SNPs (HapMap CEU r2 = 0.02).
The SSc-associated SNP rs10865710 is located within
the first intron of PPARG <1 kb from the second exon.
As a tag SNP, it is unclear whether the functional rele-
vance of rs10865710 in SSc is derived from this SNP or
another SNP that is in LD. Review of data from the
ENCODE project and 1000 Genomes Project using
HaploReg did not identify any study analyzing the func-
tional relevance of PPARG variation in cell lines relevant
to SSc pathogenesis [44,45]. More generally, these data-
bases reveal that the region tagged by rs10865710 alters
the binding motif for transcription factor Pou3f2. More-
over, several SNPs in strong LD with rs10865710 (r2 >
0.9) are located in binding regions for important regula-
tory proteins including STAT3 (rs17036242) and gluco-
corticoid receptor GR (rs13433696). While these potential
mechanisms are intriguing, there is no evidence that
rs10865710 or other SNPs in strong LD have any direct
effect on PPARG mRNA expression levels. Nor is there
evidence to date that this intronic SNP is important for
alternative mRNA splicing, epigenetic modification of
supercoiled DNA, or miRNA binding. Resequencing of
the LD block tagged by rs10865710 may be needed in
order to identify one or more SSc causal variants. As in
the present studies only common variants were assayed, it
remains possible that rare variants with a large effect could
be in LD with rs10865710 and impact gene/protein ex-
pression in a direct fashion. Deep resequencing at the
PPARG locus in SSc patients will therefore be required to
define potentially causal variants.
A survey of SCANdb [46] reveals that rs10865710 is
an eQTL for GOLGA3 (P = 3 × 10−5) and AKAP8 (P =
1 × 10−4) in European ancestry populations. GOLGA3 is
a golgi apparatus gene which is ubiquitously expressed
and does not appear to have any specificity that would
make it likely to contribute to SSc pathogenesis based
on current knowledge [47]. AKAP8 is a scaffold protein
involved in protein kinase A (PKA) signaling, and al-
though unlikely to be important in SSc, one could
hypothesize that the role of this molecule in dendritic
cell antigen presentation could be of importance, given
that plasmacytoid dendritic cells are considered import-
ant in SSc pathogenesis [48,49].
While the US and French cohorts individually found
contrasting SSc subtype associations with rs10865710, the
combined analysis showed association with both limited
and diffuse SSc subtypes. It is unlikely that differences in
clinical assessment account for this discrepancy as both
cohorts used the same criteria to define SSc subtypes. The
fact that both subtypes are significant in the meta-analysis
suggests that the contrasting associations may be due to
stochastic variability due to small sample sizes of each in-
dividual cohort, particularly in the US cohort.
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SSc-specific antibodies is not unexpected as PPARG has
no major effect on adaptive immunity. The ability to de-
tect association with ILD and especially PH were quite
likely limited by our small sample size of SSc cases mea-
sured for these phenotypes. However, the French cohort
and the meta-analysis did have enough patients with
right heart catheterization proven PH to demonstrate an
association. PPAR-γ has previously been implicated in
PH through studies of mice with targeted deletion of
PPAR-γ in arterial smooth muscle cells that spontan-
eously develop PH [50]. Given other multiple studies
suggesting an important role of PPAR-γ in pulmonary
hypertension [51,52], it is intriguing as to whether the
associated SNP may be a risk factor for severe vasculop-
athy and may warrant further study in larger populations
of patients with PH.
A limitation of this study is that the participants in
the US-European ancestry cohort self-identified as
European ancestry, so it is possible that population
genetic substructure could be the underlying cause of
the observed association. To correct for this possibility
would require genotyping of approximately 100 ances-
try informative markers, which was not feasible within
the limited scope of this study.Conclusion
In conclusion, the present studies provide evidence for as-
sociation of SSc with an intronic PPARG SNP the function
of which appears to be independent of known coding vari-
ants. These results combined with findings from previous
in vitro and in vivo studies, provide support for the poten-
tial role of PPAR-γ in the pathogenesis of fibrotic and vas-
cular complications of SSc. The observations suggest that
pharmacological regulation of PPAR-γ expression or activ-
ity might represent an innovative approach for the treat-
ment of patients with SSc.Additional files
Additional file 1: Linkage disequilibrium map for PPARG region.
Linkage disequilibrium (D’) in European ancestry population (CEU)
individuals across the entire PPARG locus, green line indicates area in
which SNPs were genotyped for the present study. The green dot
indicates the location of the systemic sclerosis SSc associated variant
rs10865710.
Additional file 2: Meta-analysis of all single nucleotide polymorphisms
(SNPs) genotyped in limited cutaneous systemic sclerosis (lcSSc) and
diffuse cutaneous systemic sclerosis (dcSSc) in the US and French
cohorts. Genotype prevalence of all SNPs genotyped separated by disease
subtype (lcSSc and dcSSc) including meta-analysis for the associated SNP
rs10865710.
Additional file 3: Association of rs10865710 with systemic sclerosis
(SSc) autoantibodies and clinical manifestations. Genotype
prevalence of the associated single nucleotide polymorphism (SNP)
rs10865710 separated by autoantibodies (anticentromere andantitopoisomerase I) and presence/absence of interstitial lung disease
and pulmonary hypertension.
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